The Use of Microdialysis for Monitoring the Effect of the Neuroprotective Drug CI-977 on Extracellular Excitatory Amino Acids
The excitatory amino acid glutamate is now accepted as an important cause of brain damage in animals following ischemia [1, 2]. Its effects can be ameliorated by various neuroprotective drugs that either block the postsynaptic N-methyl-d-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors or which putatively inhibit the presynaptic release of glutamate . In man, ischemia is a cause of brain damage, not only in stroke but also in head injury; as many as 85% of patients who die following a head injury have evidence of hypoxic ischemic brain damage [4, 5]. The use of neuroprotective drugs in these conditions could be beneficial, and there are currently several clinical studies under way.
KeywordsCerebral Blood Flow Mean Arterial Blood Pressure Excitatory Amino Acid Contralateral Hemisphere Ipsilateral Hemisphere
Unable to display preview. Download preview PDF.
- 3.McCulloch J, Bullock R, Teasdale GM (1991) Excitatory amino acid antagonists: opportunities for the treatment of ischaemic brain damage in man. In: Meldrum BS (ed) Excitatory amino acid antagonists. Blackwell, London, pp 287–326Google Scholar
- 4.Graham DI, Adams JH, Doyle D (1968) Ischemic brain damage in fatal nonmissile head injuries. J Neuropsychiatry 39: 213–234Google Scholar
- 8.Grotta J (1994) Safety and tolerability of the glutamate antagonist CGS 19755 in acute stroke patients. Stroke 25: 255Google Scholar
- 9.Muir KW, Grosset DG, Gamzu E, Lees KR (to be published) Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin PharmacolGoogle Scholar
- 10.Steinberg GK, Bell T (1991) Clinical dose-escalation safety study of the NMDA antagonist dextromethorphan in neurosurgical patients. Stroke 22: 141Google Scholar
- 12.Woods JH, Koek W, France CP, Moersch Baecher JM (1991) Behavioural effects of NMDA antgonists. In: Meldrum BS (ed) Excitatory amino acids antagonists. Blackwell, London, pp 237–264Google Scholar